Abbvie Exec Says Will Evaluate Subcutaneous Skyrizi In Induction Phase For Ulcerative Colitis; See Further EPS Expansion Beyond The High Single-Digit Compound Annual Revenue Growth Forecast From 2024 Through 2029

AbbVie, Inc. -2.52%

AbbVie, Inc.

ABBV

219.68

-2.52%

https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/Y7w6ak8fVSTKmxSCNHGfCs

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via